Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 4
2010 6
2011 7
2012 12
2013 10
2014 9
2015 3
2016 4
2017 7
2018 13
2019 8
2020 16
2021 9
2022 10
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Nabieva N, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, Fasching PA. Hack CC, et al. Among authors: haberle l. Geburtshilfe Frauenheilkd. 2024 Apr 30;84(2):e10. doi: 10.1055/a-2314-3693. eCollection 2024 Feb. Geburtshilfe Frauenheilkd. 2024. PMID: 38690326 Free PMC article.
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gass P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, Kimmig R, Reinthaller A, Becker S, Hilpert F, Janni W, Vergote I, Harter P, Emons J, Hein A, Beckmann MW, Fasching PA, Pöschke P; AGO Uterus Commission. Gass P, et al. Among authors: haberle l. Gynecol Oncol. 2024 Mar 14;183:25-32. doi: 10.1016/j.ygyno.2024.03.002. Online ahead of print. Gynecol Oncol. 2024. PMID: 38490057 Free article.
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, Fasching PA. Hack CC, et al. Among authors: haberle l. Geburtshilfe Frauenheilkd. 2024 Feb 8;84(2):185-195. doi: 10.1055/a-2238-3153. eCollection 2024 Feb. Geburtshilfe Frauenheilkd. 2024. PMID: 38344045 Free PMC article.
RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.
Behrens A, Wurmthaler L, Heindl F, Gass P, Häberle L, Volz B, Hack CC, Emons J, Erber R, Hartmann A, Beckmann MW, Ruebner M, Dougall WC, Press MF, Fasching PA, Huebner H. Behrens A, et al. Among authors: haberle l. Geburtshilfe Frauenheilkd. 2023 Nov 22;84(1):77-85. doi: 10.1055/a-2192-2998. eCollection 2024 Jan. Geburtshilfe Frauenheilkd. 2023. PMID: 38178900 Free PMC article.
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point.
Schulmeyer CE, Beckmann MW, Fasching PA, Häberle L, Golcher H, Kunath F, Wullich B, Emons J. Schulmeyer CE, et al. Among authors: haberle l. Diagnostics (Basel). 2023 Oct 25;13(21):3300. doi: 10.3390/diagnostics13213300. Diagnostics (Basel). 2023. PMID: 37958196 Free PMC article.
Predicting mammographic density with linear ultrasound transducers.
Behrens A, Fasching PA, Schwenke E, Gass P, Häberle L, Heindl F, Heusinger K, Lotz L, Lubrich H, Preuß C, Schneider MO, Schulz-Wendtland R, Stumpfe FM, Uder M, Wunderle M, Zahn AL, Hack CC, Beckmann MW, Emons J. Behrens A, et al. Among authors: haberle l. Eur J Med Res. 2023 Sep 28;28(1):384. doi: 10.1186/s40001-023-01327-9. Eur J Med Res. 2023. PMID: 37770952 Free PMC article.
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.
Tzschaschel M, Friedl TWP, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, Schindlbeck C, Schneeweiss A, Schreier J, Tesch H, Lorenz R, Aivazova-Fuchs V, Häberle L, Fasching P, Janni W, Rack BK, Fink V. Tzschaschel M, et al. Among authors: haberle l. Clin Breast Cancer. 2023 Aug;23(6):e345-e353. doi: 10.1016/j.clbc.2023.05.011. Epub 2023 May 23. Clin Breast Cancer. 2023. PMID: 37336651 Clinical Trial.
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Fasching PA, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, Hack CC, Fehm TN, Janni W, Hartmann A, Erber R, Theuser AK, Brucker SY, Hartkopf AD, Untch M. Fasching PA, et al. Among authors: haberle l. Eur J Cancer. 2023 May;184:1-9. doi: 10.1016/j.ejca.2023.01.001. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36871424 Free article. Clinical Trial.
111 results